Last updated: 2026-09-06 07:49:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Cardiff Oncology, Inc. (CRDF) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $1.08, with a market capitalization of $82.46M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.76 to $3.31. This page covers its latest market performance, valuation, price trends and company information.
$82.46M | |
$1.12 | |
$25.50 | |
$0.76 | |
$1.08 | |
425.92K | |
-- | |
-- | |
$3.31 | |
$0.76 | |
-- | |
-- |
Cardiff Oncology, Inc. (CRDF) last closed at $1.08 as of 2026-09-04 23:31:00, unchanged from the previous close of $1.08.
During the latest regular trading session, CRDF traded between $0.76 and $25.50, with a volume of 425.92K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Cardiff Oncology, Inc. (CRDF) moved from $0.94 to $1.08, representing a gain of 14.78% ($0.14).
The stock traded between $1.07 and $1.12 during the period. The latest price is near the lower end of the 7-day range, indicating strong upward.
The average daily volume was 525.63 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 12.6%
CRDF is currently trading at $1.08, placing it 12.6% of the way from its 52-week low of $0.76 to its 52-week high of $3.31. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 31 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Cardiff Oncology, Inc. (CRDF) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.